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Abstract
Hox genes play important roles in haematopoietic development in mammals. ASH1 is a member of the trithorax group
(trxG) that is required for proper expression of Hox genes and is preferentially expressed in haematopoietic stem cells. We
have recently reported that ASH1 methylates histone H3 at lysine 36 (K36) but its biological function has remained elusive.
Here we show that ASH1 regulates Hox gene expression positively and negatively in a leukemic cell line K562 and is
required for myelomonocytic differentiation of murine haematopoietic stem cells. ASH1 binds to endogenous Hox loci in
K562 cells and its knockdown causes reduced expression of Hox genes. In addition, ASH1 and MLL1 induce more than 100-
fold activation of Hox promoters in HeLa cells if expressed simultaneously but not individually. Notably, ASH1 harbouring a
point mutation that kills methyltransferase activity is more efficient than wild type ASH1 in Hox gene activation, indicating
that K36 methylation is not a prerequisite for Hox gene expression. Moreover, tethering wild type or catalytically inactive
methyltransferase domain of ASH1 to a heterologous promoter causes downregulation or upregulation, respectively, of
transcription, supporting a hypothesis that K36 methylation imparts repression. Knockdown of ASH1 in K562 cells in vitro
causes increased expression of e-globin gene and reduced expression of myelomonocytic markers GPIIb and GPIIIa, whereas
knockdown of ASH1 in murine haematopoietic stem cells in vivo results in decreased number of macrophages and
granulocytes, a phenotype similar to that induced by loss of mll1 function. Taken together, our data suggest that ASH1 and
MLL1 synergize in activation of Hox genes and thereby regulate development of myelomonocytic lineages from
haematopoietic stem cells.
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Introduction
Hox genes are arranged in tandem arrays in the genome, and
their spacio-temporal expression patterns are regulated by
antagonistic functions of Polycomb-group (PcG) and trithorax-
group (trxG) proteins which define expression domains of Hox
genes in the genome as well as along the body axis[1–3]. Loss of
either PcG or trxG results in misexpression or loss of expression of
Hox genes, respectively, resulting in homeotic transformations of
body segments. ASH1 was discovered by screens of imaginal disc
mutants in Drosophila melanogaster[4]. ASH1 is a member of trxG
and loss of its function causes anterior transformations similar to
those in trx mutants[5]. Trans-heterozygous ash1/trx mutants
exhibit more severe phenotype at higher penetrance than single
mutants, providing genetic evidence for interaction between ASH1
and TRX in Hox gene regulation[6].
We have previously reported that ASH1 methylates histone H3
selectively at K36[7], which has been confirmed by two
independent studies of other laboratories[8,9]. There is also genetic
evidence for antagonism between ASH1 and K36 demethylase
dKDM2 in Drosophila[10], strongly supporting the specificity of
ASH1 for K36. TRX and its mammalian homologues MLL1-4 are
known to methylate histone H3 lysine 4 (K4)[11,12]. Precisely how
trxG regulates activities of RNA polymerase II remains elusive. The
observation that loss of both PcG and trxG restores expression of
Hox genes in normally expressed domains implies that trxG is not
essential for Hox gene expression but functions primarily by
counteracting repressive effects of PcG[13]. Lending support for
such a hypothesis, K36 methylation has been recently shown to
directly interfere with K27 methylation by PRC2 of PcG[8,14]. An
alternative mechanism of counteracting repressive effects of PcG
might be removal of K27 methylation marks by demethylase
enzymes contained in MLL family complexes[15,16]. Reciprocally,
K36 demethylase dKDM2 constitutes a PcG subcomplex of
dRING[10], suggesting that PcG might antagonize trxG by
removing K36 methylation marks. These findings collectively
suggest that Hox genes are regulated by dynamic balance between
mutually exclusive methylation status of K36 and K27 through
competing actions of methyltransferases and demethylases. How-
ever, there has been no evidence showing that K36 methylation
contributes to Hox gene activation by inhibiting K27 methylation.
Recently, trxG complexes have been shown to contain an
essential elongation factor P-TEFb, raising a possibility that trxG
might directly affect the rate limiting step of RNA synthesis[17].
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8Thus, RNA polymerase complexes are ‘‘paused’’ at immediate
downstream of transcription initiation site in many developmen-
tally regulated genes[18], and CDK9 activates transcription by
phosphorylating and inducing dissociation of NELF/DSIF that
anchor RNA polymerase II[19,20]. The N-terminal part of
mammalian ASH1 is most similar to SETDB1[7,21]. Notably,
both SETDB1[22] and MLL1[23] are known to interact with SET
oncoprotein and protein phosphatase 2A (PP2A), latter of which
could negatively regulate P-TEFb[24]. It thus appears that trxG
contains/interacts with both the molecular switch of transcription
(P-TEFb) and its regulators (SET/PP2A).
Hox genes play important roles in haematopoietic develop-
ment[25] and mutations of the mll1 gene is the major cause of
infant leukaemia[26,27]. Expression of MLL-AF9 translocation
products in murine myeloid precursor cells has been shown to
induce leukaemia in association with altered expression patterns of
‘‘stem cell genes’’[28,29]. Therefore, understanding molecular
mechanisms of how trxG proteins regulate target genes in
haematopoiesis has clinical implications for combating leukaemia.
ASH1 is preferentially expressed in haematopoietic stem cells in
the bone marrow[30] and undifferentiated precursors of T cells in
the thymus[31], suggesting that ASH1 might play a role in
haematopoietic development. In the current study, a full-length
ASH1 expression vector was used to directly assess biochemical
function of ASH1 in Hox gene activation in vitro. We show that
ASH1 synergizes strongly with MLL1 to activate Hox genes.
Contrary to expectations, however, our data indicate that K36
methyltransferase activity of ASH1 causes repression rather than
activation of Hox genes. We also show that function of ASH1 and
MLL1 is required for normal development of myelomonocytic
lineages from murine haematopoietic stem cells in vivo.
Results
ASH1 is required for endogenous Hox gene expression
To assess the role of ASH1 in regulation of endogenous Hox
gene expression, we analysed the impact of ASH1 knockdown on a
human erythroleukaemia cell line K562[32]. To this end, K562
cells were transfected with either siRNA for ASH1 (si6925) or a
control scrambled sequence and levels of endogenous Hox genes
were quantitated by RT-PCR. Hox genes in Hox-B and Hox-C
clusters were analysed because these are expressed in K562 cells as
judged by the presence of both RNA polymerase II and active
chromatin marks such as K4me3 and K36me3 (Fig. S1). As
illustrated in Fig. 1A, si6925 reduced the level of ASH1 to
approximately half of the control. Notably, si6925 caused down-
regulation of Hox-B2, B3, B5, B6, B7, C4, C6, and C8 to various
degrees. These effects were marginal probably because of
incomplete depletion of ASH1 by si6925, which might also
explain why HoxC9 was not affected by ASH1 knockdown since
HoxC9 appears to be transcribed more actively than other genes
in the HoxC cluster as judged by H3K4 methylation (Fig. S1).
Nevertheless, b-actin (Fig. 1A), c- and b-globin genes, GATA1,
and KLF1 (Fig. 1B) were not affected by si6925, indicating that the
effects are gene specific. In addition, expression of both GPIIb and
GPIIIa were reduced by ASH1 knockdown (Fig. 1B), supporting
the consistency of the effect of ASH1 knockdown. Therefore, these
data suggest that ASH1 is required at least partially for expression
of HoxB and HoxC genes in K562 cells.
Next, to determine if ASH1 directly regulates Hox gene
expression, binding of ASH1 proteins to endogenous Hox loci
was assessed by chromatin immunoprecipitation analysis. The
HoxC8 gene was first examined because it is expressed in K562
cells, is affected by ASH1 knockdown, and has been also shown to
be regulated by MLL1[12,33]. Fig. 1C and 1D shows that ASH1 is
associated with both promoter-proximal regions near the tran-
scription start site and downstream regions of the HoxC8 and
HoxB6 genes. These data were obtained by using anti-ASH1
antibodies specific for an internal epitope. Similar experiments
using antibodies against the C-terminal end of ASH1 showed less
pronounced but similar binding patters of ASH1 to the promoter
and downstream region of the HoxC8 gene (Fig. S2). These data
are consistent with a recent study showing that ASH1 binds to
extended regions of actively transcribed Hox genes in Drosophi-
la[34] and support a hypothesis that ASH1 directly regulates
transcription of Hox genes through interaction with both
promoter and downstream regions of the genes.
ASH1 and MLL1 co-operates in Hox promoter activation
in vitro
ASH1 and TRX belong to trxG and have been shown to
genetically interact with each other in Drosophila[5,6]. In
mammals, MLL1 has been shown to be required for Hox gene
expression[35], and introduction of full-length MLL1 into mll1-
deficient murine fibroblasts restores expression of HoxC8 and
HoxA9 genes[12]. MLL1 is also known to associate with HoxA9
promoter in HeLa cells[11]. To examine if ASH1 and MLL1
interact with each other in mammalian cells, we used luciferase
reporter constructs harbouring HoxC8 and HoxA9 promoters
(Fig. 2A). HeLa cells which express minimal levels of Hox genes
were transiently transfected with Hox promoter-renilla luciferase
reporter plasmids together with CMV-firefly luciferase reporter
and expression vectors of either MLL1 or ASH1, or both. As
illustrated in Fig. 2B (HoxC8) and 2C (HoxA9), expression of
MLL1 or ASH1 alone had little impact on Hox and control CMV
promoters. By contrast, co-expression of MLL1 and ASH1 caused
marked activation of HoxC8 and HoxA9 promoters by 50 to 150-
fold (Table S2). The CMV promoter was also activated by several-
fold but the effects were 10 to 20-fold more pronounced for Hox
promoters (C8 or A9/CMV ratios in Fig. 2C). These effects were
also dose-dependent since increasing amount of ASH1 or MLL1
in the presence of fixed amount of MLL1 or ASH1, respectively,
caused stronger activation of Hox promoters (Fig. S3).
Despite the clear evidence that co-transfection of ASH1 and
MLL1 expression vectors causes strong activation of Hox
promoters, ASH1 proteins of a predicted molecular weight failed
to be detected by Western blot analysis using antibodies against
ASH1(C-terminalend orinternal)ortheN-terminalFLAGtag.We
therefore constructed several deletion mutants of ASH1 and found
that ASH1
D216-1283 lacking a part of the N-terminal SETBP1
homology domain of ASH1 could be detected by Western blot (Fig.
S4B) and possessed a Hox promoter activation potential as good as
wild type ASH1 (Fig. 2C). The C-terminal part of ASH1, i.e.
ASH1
1851-2964 which harbours all the chromatin-associated motifs
but lacks the SETBP1 homology domain, could be detected by
Western blot (Fig. S4B) and caused activation of the HoxA9
promoter. Thus, the C-terminal part of ASH1 is largely sufficient to
co-operate with MLL1 to regulate Hox gene expression.
K36 methylation by ASH1 has a gene repressive effect
A point mutation in the SET domain of TRX in Drosophila
prevents methylation of histone H3 K4 and causes homeotic
phenotypes[36]. In addition, mutation of ASH1 in flies results in
reduction of histone H3 K4 methylation[37], suggesting that
ASH1 plays an important role in regulation of the methyltrans-
ferase activity of TRX. However, it remains to be shown if
methylation of K36 by ASH1 is required for Hox gene activation.
To address this issue, we used an expression vector of ASH1
K36 Methylation by ASH1 Causes Gene Repression
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histidine
2113 with lysine inside the coenzyme binding pocket) that
kills the methyltransferase activity[7]. Surprisingly, co-expression
of MLL1 and the catalytically inactive ASH1
H2113K induced twice
as strong activation of HoxA9 as wild type ASH1 as shown in
Fig. 2B. By contrast, ASH1
H2113K alone had little impact on Hox
promoters, suggesting that the mutant ASH1 is still functionally
dependent on MLL1.
Figure 1. Regulation of endogenous Hox genes by ASH1. (A) Quantitative RT-PCR analysis of HoxB and HoxC gene expression in K562 cells.
Expression levels are normalized against average of K562 cells transfected with scrambled oligonucleotides. ASH1 knockdown oligonucleotides
(si6925) causes reduction of ASH1 and several HoxB and HoxC genes, whereas b-actin is not affected. Values are average of triplicates of K562
samples and error bars denote standard deviation. (B) Effects of ASH1 knockdown on erythroid and monocytic marker gene expression in K562 cells.
ASH1 knockdown causes increased expression of the e-globin gene and decreased expression of GPIIb and GPIIIa genes. Transcription factors
required for globin gene expression such as GATA1 and ELF1 are not affected. Data represent triplicate K562 samples and error bars indicate standard
deviation. (C–D) Chromatin immunoprecipitation analysis of ASH1 in the HoxC8 (C) and HoxB6 (D) genes of K562 cells using antibodies against an
internal epitope of ASH1. Quantitative PCR signals are shown by proportion to those of input DNA. GAPDH promoter is a negative control to which
ASH1 does not bind. ASH1 is associated with promoter and coding regions of HoxC8 and HoxB6 genes. Values are average of triplicates of
independent ChIP samples and indicate semi quantitative PCR signals relative to input DNA. Statistically significant differences (Student’s t-test) are
indicated by asterisks (*: p-value , 0.05, **: p-value , 0.01).
doi:10.1371/journal.pone.0028171.g001
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gene activation could be due to an artificial condition of using
episomal targets that may not be organized in proper chromatin
structure[38]. To test such a possibility, we next analysed the effect
of ASH1
H2113K on endogenous Hox genes. As shown in Fig. 3A,
expression of ASH1
H2113K alone in K562 cells augmented
expression of endogenous HoxC8 gene approximately by 2.5-
fold. By contrast, wild type ASH1 had little effect on endogenous
Hox genes. These data suggest that methyltransferase-deficient
ASH1
H2113K is more efficient than wild type ASH1 in Hox gene
activation, clearly indicating that K36 methylation is not
prerequisite for Hox gene activation contrary to a hypothesis that
ASH1 might activate Hox genes by methylating K36 and thereby
interfering with K27 methylation by PRC2[8].
Tethering of catalytically inactive ASH1 to a heterologous
promoter causes gene repression
5Neither ASH1
H2113K nor wild type ASH1 affected endoge-
nous Hox genes when co-transfected with MLL1 (Fig. 3A). This
would be unexpected if hyper-activation of Hox genes by
ASH1
H2113K were mediated simply by increased amount of
ASH1 and MLL1 proteins binding to more Hox targets. A
possible explanation may be that exogenous ASH1
H2113K
replaced endogenous ASH1 that is already bound to Hox targets
and caused reduction of K36 methylation and consequently
derepression of Hox genes. To clarify this issue, we directly tested
if ASH1-mediated K36 methylation has a gene repressive effect
by artificially tethering its SET domain to the c-fos promoter
through a GAL4-DNA-binding domain (DBD). As illustrated in
Figure 2. Activation of Hox promoters by ASH1 and MLL1. (A) Luciferase reporter constructs harbouring human HoxC8 (2600 to +186) and
HoxA9 (2637 to +56) promoters. (B) Activation of HoxC8-firefly luciferase and CMV-renilla luciferase reporters by MLL1, ASH1, or both together in
HeLa cells. HoxC8-specific effects are shown by C8/CMV ratios. Values are average of triplicates of independently transfected HeLa cells and error bars
denote standard deviation. (C) Similar to (B) but using HoxA9-firefly luciferase vector and ASH1 mutants including catalytically inactive ASH1 (H2113K)
which induces twice as strong activation of HoxA9 (but not CMV) promoter as wild type ASH1. ASH1
1851-2694 that consists of the C-terminal region has
significant activity towards HoxA9. ASH1
D216-1283 lacking a part of the N-terminal region can be detected by Western blot and has the same
transactivation potential as wild type ASH1.
doi:10.1371/journal.pone.0028171.g002
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transfected with wild type ASH1 SET domain (DBD-ASH1) than
in cells transfected with DBD alone, suggesting that the wild type
ASH1 SET domain has a gene repressive effect. By contrast,
transfection of DBD-H2113K harbouring the catalytically
inactive ASH1 SET domain induced higher levels of reporter
gene expression than control GAL4-DBD, suggesting that the
ASH1 SET domain has an intrinsic ability to activate
transcription above background levels. Compared to DBD-
H2113K, DBD-ASH1 attenuates reporter gene expression by
approximately three-fold, which is comparable to gene repression
observed by fusing GAL4-DBD to Symd2 that is a K36
methyltransferase[39].
ASH1 regulates myelomonocytic development
K562 cells transfected with ASH1 knockdown oligonucleotides
turned light pink in colour (implying haemoglobin synthesis),
prompting us to further analyse expression of lineage markers. As
illustrated in Fig. 1B, knockdown of ASH1 caused upregulation of
the e-globin gene and downregulation of myelomonocytic markers
GPIIb and GPIIIa, suggesting that ASH1 may be involved in
erythroid vs. myelomonocytic cell fate determination. K562 cells
are derived from blast crisis of chronic myelogenous leukaemia
patient[40] and has been shown to undergo erythroid differenti-
ation upon various stimulations such as haemin and chemother-
apeutic agents[32,41]. Our observation that e- but not c-o rb-
globin genes was affected by ASH1 knockdown is consistent with
previous reports showing that K562 cells synthesize only foetal
type globins[32]. Quantitation of globin gene transcription factors
such as GATA1 and KLF1 revealed no changes upon ASH1
knockdown (Fig. 1B), implying a distinct mechanism for regulation
of globin genes.
The effect of ASH1 knockdown on gene expression in K562
cells could just reflect the partially committed nature of K562 cell
line. To further assess the role of ASH1 in normal haematopoiesis
in vivo, lineage marker-negative haematopoietic progenitor cells
were isolated from the bone marrow of C57BL/6J-Ly5.1 mice,
transduced with lentiviral vectors expressing either control GFP or
siRNA for ASH1 or MLL1, and then transferred into sublethally
irradiated C57BL/6J mice (Ly5.2 allotype). Commitment of
donor-derived progenitor cells into different lineages was assessed
by flow cytometric analysis of peripheral blood using antibodies
against Cd11b (macrophages), Gr-1 (granulocytes), CD19 (lym-
phocytes), TCRb (T cells), and TER119 (erythrocytes). As shown
in Fig. S6, there is a clear tendency that there are fewer CD11b
+
and Gr-1
+ cells and more CD19
+ cells among donor-derived Ly5.1
(CD45.1)
+ cells expressing siRNA for ASH1 or MLL1 than in
those expressing control GFP. Representative FACS profiles as
depicted in Fig. 4 shows that knockdown of ASH1 and MLL1 in
haematopoietic progenitor cells skews differentiation from myelo-
monocytic (CD45.1
+CD11b
+ and CD45.1
+Gr-1
+ cells) towards
lymphoid (CD45.1
+CD19
+ cells) or erythroid (CD45.2
-TER119
+
cells) lineages as compared to progenitor cells expressing control
GFP. The effects of MLL1 knockdown are highly consistent with
previous studies showing that mll1 knockout in mice causes
reduction in the number of myeloid and macrophage colonies in
culture of yolk sac and bone marrow cells[42,43]. Taken together,
these data suggest that ASH1 functions in the same genetic
pathway as MLL1 to facilitate myelomonocytic differentiation of
haematopoietic stem cells.
Figure 3. Function of methyltransferase-deficient ASH1. (A) Effect of ASH1 and its mutants on endogenous HoxC8 (closed bars) and HoxB6
(open bars) genes in K562 cells. Catalytically inactive ASH1
H2113K augments endogenous Hox genes. Data represent triplicate K562 samples and error
bars indicate standard deviation. Endogenous HoxC8 activation by ASH1
H2113K is statistically significant (*: p-value , 0.05). (B) Top: a reporter
construct harbouring GAL4 binding sequences (x4) and c-fos promoter. Bottom: Expression vectors carrying GAL4-DNA binding domain (DBD), DBD
fused to wild type ASH1 SET domain (DBD-ASH1), or DBD fused to catalytically inactive ASH1 SET domain (DBD-H2113K) were co-transfected with the
reporter into HeLa cells. Wild type ASH1 SET domain is approximately 3-fold less efficient than catalytically inactive ASH1 SET domain, suggesting that
K36 methylation attenuates transcription. Data represent triplicate HeLa samples and error bars indicate standard deviation. Differences between
DBD and DBD-ASH1 and between DBD-ASH1 and DBD-H2113K were statistically significant (*: p-value , 0.01).
doi:10.1371/journal.pone.0028171.g003
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ASH1 is known to interact with trxG and PcG genes in
regulation of Hox gene expression[5,6,13], but the molecular
mechanism of how ASH1 regulates Hox genes has been largely
unknown. The current study using reporters carrying HoxC8 and
HoxA9 promoters demonstrated that mammalian ASH1 and
MLL1 synergize strongly in transcriptional activation of Hox
promoters, providing a basis for biochemical analysis of transcrip-
tional regulation. Using such a system, we provided evidence that
the methyltransferase activity of ASH1, and K36 methylation by
inference, is not required for Hox gene activation but rather
imparts repression. Of note, recent studies have revealed that K36
methylation interferes with K27 methylation by PRC2[8,14]
providing a possible mechanism of how ASH1 might counteract
repressive effects of PcG[13]. Importantly, however, functional
consequences of K36 methylation were not directly addressed in
these studies. Our data clearly indicate that K36 methylation is not
the major mechanism of how ASH1 activates targets, given that
catalytically inactive ASH1 was more efficient than wild type
ASH1 in Hox gene activation (Fig. 2C). Taken together, these
observations might imply that K36 methylation represents a state
of repression distinct from K27 methylation. ASH1 may
antagonize PcG repression by preventing ‘‘deeper’’ silencing by
K27 methylation.
In ash1 mutant flies, Antennapedia (Antp) promoter-reporter gene
has been found ectopically expressed in larvae along the anterior
margin of haltare discs where Antp is not normally expressed[44],
Figure 4. Effect of ASH1 knockdown on haematopoiesis. Representative FACS plots of peripheral blood from mice transplanted with control
GFP or knockdown vectors for ASH1 or MLL1. Horizontal axis represent CD45.1 (donor allotype) or CD45.2 (recipient allotype) and vertical axis
indicates lineage markers: CD11b (macrophages), Gr-1 (granulocytes), CD19 (B cells), TCRb (T cells), and TER119 (erythrocytes).
doi:10.1371/journal.pone.0028171.g004
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domains. Consistent with such a notion, we have reported that
expression of the protein-protein interaction domain of ASH1 (i.e.
PHD finger) causes increased expression of Hox genes presumably
by a dominant negative effect[31]. MLL1 is also known to interact
with a transcriptional repressor Sin3A[11], suggesting that trxG
could have gene repressive function. In yeast, co-transcriptional
methylation of K36 confers memories of recent transcription to
cells and represses spurious intragenic transcription initiation
through recruitment of Rpd3[45]. Our finding that K36
methylation by ASH1 causes gene repression is consistent with
these studies and underscores a notion that trxG proteins have
dual function in Hox gene activation.
Recent findings that TRX/MLL-family proteins interact with
P-TEFb imply that trxG complexes might regulate transcription
by releasing ‘‘paused’’ RNA polymerase II[17]. Activities of P-
TEFb is thought to be regulated by sequestration into inactive
compartment by 7SK snRNP and HEXIM proteins, and
dephosphorylation by protein phosphatase 1 and PP2A[46].
Although it remains to be shown how trxG complexes regulate
the activity of P-TEFb, it is of note that MLL1 interacts with PP2A
through oncoprotein SET [23] and that the N-terminal part of
ASH1 is most similar to SETBP1 that also interacts with
oncoprotein SET[7,22]. SET oncoproteins are known to inhibit
the activity of PP2A and thus are expected to activate P-TEFb.
Consistent with such a hypothesis, we found that okadaic acid
enhances activation of the HoxA9 promoter (but not the CMV
promoter) in the presence of ASH1 and MLL1 at a concentration
that blocks PP2A (Fig. S5). However, C-terminal region of ASH1
lacking the SETBP1 homology domain has a significant Hox
promoter activation potential (Fig. 2C), suggesting that there is yet
unknown function of ASH1 for activation of Hox genes.
Our in vivo knockdown experiments show that ASH1 and MLL1
play important roles in myelomonocytic development, consistent
with previous studies showing that targeting the mll1 gene causes
severe defects in myelomonocytic development in yolk sac and
bone marrow[42,43]. By contrast, more recent studies on
conditional knockout of mll1 demonstrated that MLL1 is not
required for postnatal steady-state haematopoiesis but plays an
important role in maintenance of stem cell pools in a quiescent
state[47,48]. The cause of such discrepancy is unknown but a
possible explanation may be difference in timing and cell type
specificity of transgenic Cre-mediated conditional deletion of mll1
gene and lentivirus-mediated knockdown of mll1. Nevertheless,
under the same experimental conditions in our system, depletion
of ASH1 and MLL1 caused similar phenotypes reinforcing the
idea that ASH1 and MLL1 synergize in regulation of haemato-
poietic development. Further studies on target genes of ASH1 and
MLL1 might reveal precise molecular functions of these epigenetic
regulators in normal haematopoietic development as well as in
leukaemias caused by mutations of mll1[28].
Materials and Methods
Ethics statement
All animal works were approved and conducted according to
the guidelines of Committees of Animal Experiments and
Recombinant DNA Experiments of Tokyo Medical and Dental
University (License number: 2010-205).
Cells and culture
Human erythroleukaemia cell line K562 (strain RCB0027) was
obtained from Riken Cell Bank, was able to synthesize globin in
response to sodium butyrate, and was cultured in Ham-F12
containing 10% FCS (Invitrogen). HeLa cells were from Dr. H.
Handa (Tokyo Institute of Technology) and were cultured in
DMEM containing 10% FCS.
Vectors and cloning strategy
Full length human ash1 cDNA (8892 bp) was cloned from
HeLa cells by sequentially joining PCR fragments into EcoRI/
XbaI sites of pCMV-tag2C (Invitrogen) to obtain pCMV-F-
ASH1. Subsequently, NotI/XhoI fragment of pCMV-F-ASH1
was subcloned into EcoRI site of pCI-neo (Promega) to obtain
pCI-F-ASH1. pCI-F-ASH1
1-2050 was constructed with NotI/
EcoRV fragment of pCMV-F-ASH1 by blunt end ligation into
pCI-neo EcoRI site. To generate pCI-F-ASH1
1851-2694, SalI/
XhoI fragment of pCMV-F-ASH1 was subcloned into the same
sites of pCMV-tag2C, from which NotI/XhoI fragment was cut
out and blunt end ligated into pCI-neo EcoRI site. A histidine to
lysine substitution was introduced into ASH1 at position 2113 by
Site Directed Mutagenesis Kit (Stratagene) on pCI-F-ASH1.
Human Hox promoter-luciferase vectors were constructed by
ligating HindIII/NotI PCR fragments into the same sites of pGV-
B2 (Picagene) after amplification of -600 to +186 of HoxC8 and -
636 to +54 of HoxA9 promoter from BAC clones, RP11- and
RP11-1134K14, respectively obtained from Dr. Inazawa (TMD,
Japan). A control vector pRL-CMV, that contains the CVM
promoter, was also obtained from Picagene. Expression vectors for
MLL1 and MLL-AF9 were king gifts from Drs. Seto and Hess,
respectively. pWHGA was a kind gift from Dr. Ptashne.
Gal4DBD-ASH1 expression vectors was constructed from
pGEX-6P-ASH1 vectors. Lentivirus vectors and packaging
plasmids pENTR4-H1, CS-RfA-EG, pCAG-HIVgp, and
pCMV-VSV-G were obtained from Riken Bioresource Center
(Japan). Mouse ASH1 and MLL1 knockdown vectors were
constructed by first cloning synthetic shRNA oligonucleotides into
BglII and XbaI sites of pENTR4-H1 and then subcloning into CS-
Raf-EG using Gateway LR Clonase (Invitrogen). Primers used of
PCR cloning and mutagenesis are listed in Supplementary
materials.
Gene knockdown
Knock-down siRNA were designed by iGENE Therapeutics
Inc., Japan, and double strand RNA was synthesized together with
a scrambled sequence with minimal off-site effect by Hokkaido
System Science (Japan). For electroporation, 1610
5 K562 cells
were mixed with 0.5 mg siRNA in Electrolytic Buffer E and pulsed
at 1200 V for 50 msec using MP-100 (Digital Bio Tech), and then
put back in Ham-F12 with 10% FCS. After 48 hours, cells were
harvested and total RNA prepared with ISOGENE (Nippon
Gene). Total RNA was reverse transcribed using RNA PCR Kit
(AMV) Ver. 3.0 (TaKaRa-Bio, Japan) according to manufacturer’s
protocol. Subsequently, first strand cDNA was amplified using
Power SYBR Green Master Mix and 7900HT Fast Real Time
PCR System (Applied Biosystems). Relative amount of templates
was given by 2
-DDCT, where DDCT= (Ct
target -C t
GAPDH)si6925 -
(Ct
target -C t
GAPDH)control. Sequences of oligonucleotides are listed
in Table S1.
Chromatin immunoprecipitation
K562 and HeLa cells were fixed with 3.6% formaldehyde at
room temperature, blocked with 0.2 M glycine, lysed, and
sonicated using Bioraptor UCD-250 (BM Equipment Coorp.,
Japan). Antibodies against C-terminal end of ASH1 or internal
epitope of ASH1 (Santa-Cruz) were added and immunoprecipi-
tated with Protein G-agarose coated with sermon sperm DNA
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quantified by real time PCR as in gene knockdown.
Luciferase assay
HeLa cells were synchronised by double thymidine block and
plated in 24-well plates at 5610
4 cells/well, transfected with
0.5 mg pGV-HoxC8 or pGV-HoxA9, 0.01 mg pRL-CMV, with or
without 0.5 mg pCI-F-ASH1, pCXN2-MLL1, or pCI-neo to
adjust total amount of plasmid using Superfect Reagent (Qiagen).
After culture for 6 hours in the presence of 2 mM thymidine, cells
were rinsed and incubated for further 9 hours to allow one round
of cell cycle, after which 2 mM thymidine was added back to keep
cells at G1/S boundary. At 48 hours after transfection, cells were
lysed, protein content adjusted, and luciferase activity was
measured using Dual-Luciferase Reporter Assay System (Promega)
on Lumat LB9501 (Berthold).
Bone marrow transfer and flow cytometric analysis
Haematopoietic progenitors were purified from bone marrow of
C56BL/6J-Ly5.1 female mice by depleting lineage marker
+ cells
using MagCellect Mouse Haematopoietic Cell Lineage Depletion
Kit (R&D Systems). Approximately 3.3610
5 progenitor cells were
then transduced with CS-CDF-EG-PRE, CS-H1-siAsh1-EG, or
CS-H1-siMll1-EG lentiviral vectors in the presence of 100 ng/ml
SCF, 10 ng/ml TPO, and 10 ng/ml Flt3-L for 24 hours, and
subsequently injected intravenously into five C57BL/6J-Ly5.2
recipient female mice which had been c-irradiated by 950 cGy.
After 4 weeks, mice were sacrificed and peripheral blood
was analysed using CD45.1
PE, CD45.2
biotin, CD11b
APC,
Gr-1
APC, CD19
Tricolour, TCRb
APC, TER119
PE antibodies (BD
Pharmingen) and streptoavidin
Tricolour (Caltag) on FACSCalibur
(BD Bioscences).
Supporting Information
Figure S1 Hox code of K562 leukemic cell line. ChIP-seq
data of histone H3 trimethylation at K4, K27, and K36 and RNA
polymerase II developed by Broad Institute were obtained from
the ENCODE database[49]. The raw data were mapped to the
human genome GRCh37/hg19 assembly using bwa[50] and peak
detection was carried out using MACS[51]. Presence or absence of
activation marks (K4me3, K36me3, and Pol2) and a repression
mark (K27me3) indicate that subsets of HoxB and HoxC genes are
transcribed in K562 cells whereas HoxA and HoxD loci are
largely silent.
(TIF)
Figure S2 ChIP analysis of the HoxC8 promoter using
antibodies against the C-terminal end of ASH1. ChIP
analysis was carried out as in Fig. 1B using house-made rabbit
polyclonal antibodies against the C-terminal epitope of ASH1.
Preferential bindings of ASH1 to the promoter as well as
downstream region of HoxC8 are shown.
(TIF)
Figure S3 Titration of ASH1 and MLL1 in Hox gene
activation. HeLa cells were transfected with either fixed amount
(1 mg) of MLL1 and different amount of ASH1 expression vectors
(closed circles) or fixed amount (1 mg) of ASH1 and different
amount of MLL1 (open circles) together with HoxA9-luciferase
reporter. Luciferase activities corrected by CMV-renilla luciferase
activities are plotted. ASH1 and MLL1 shows first order and
seconder order reaction kinetics, respectively.
(TIF)
Figure S4 Deletion mutants of ASH1. Despite the clear
evidence that full-length ASH1 has a strong transactivation
potential, it is hardly detectable by Western blot analysis[7,52].
We constructed a series of deletion mutants of ASH1 to identify
fragments which can be detected and quantified by Western blot.
Mutants in group (A) are not detectable and those in group (B) are
detectable by Western blot. Inclusion of region III and either
region I or region II of the N-terminal part of ASH1 appears to
render proteins invisible by Western blot. The largest ASH1
mutant that can be identified at a protein level is ASH1
D216-1283
and it has a Hox promoter activation potential comparable to that
of wild type ASH1 (Fig. 2C).
(TIF)
Figure S5 Hox promoter is sensitive to low dose okadaic
acid. HeLa cells were transfected with HoxA9-firefly luciferase
(open squares) and CMV-renilla luciferase (closed squares) vectors
together with ASH1 and MLL1 expression vectors (1 mg each) in
the presence of absence of okadaic acid. Okadaic acid enhances
transcription of HoxA9 but CMV promoter at a concentration of
1 nM which is known to inhibit protein phosphatase 2A but not
protein phosphatase 1A, suggesting that Hox promoter activation
by ASH1 and MLL1 is sensitive to the activity of protein
phosphatase 2A.
(TIF)
Figure S6 Effects of ASH1 and MLL1 knockdown on
haematopoiesis. Effects of ASH1 and MLL1 knockdown on
haematopoietic development in vivo. Purified haematopoietic stem
cells were transduced with lentiviral vectors expressing control
GFP (closed bars) or shRNA for ASH1 (hashed bars) or
MLL1(open bars) and transplanted into sublethally irradiated
mice. Donor-derived cells were distinguished from host cells by
Ly-5.1/Ly-5.2 allotypes, and proportions of lineage marker-
positive cells among donor-derived cells are indicated. Knockdown
of MLL1 caused statistically significant (p,0.05) reduction in the
number of cells expressing CD11b (macrophages) or Gr-1
(granulocytes) and reciprocal increase in the number of lymphoid
cells expressing CD19. The effects of ASH1 knockdown were not
statistically significant but were similar to those of MLL1
knockdown.
(TIF)
Table S1 Oligonucleotide sequences. Sequences of oligo-
nucleotides used for RT-PCR, ChIP-PCR, knockdown experi-
ments, and cloning.
(DOC)
Table S2 Hox promoter-luciferase reporter experi-
ments. Raw readings of firefly and renilla luciferase activities
using Dual-Luciferase Reporter Assay System (Promega).
(XLS)
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